Rättskällor med officiella primärkällor

Utskrivet ·

Skip to main content
Skip to the answer

Back to the decisions

Court of Justice of the European Union · Judgment

C-557/16Proceedings brought by Astellas Pharma GmbH

Decided
2018-03-14
ECLI
ECLI:EU:C:2018:181
CELEX
62016CJ0557
Finality
Final, the decision cannot be appealed

The court's own keywords

Reference for a preliminary ruling — Directive 2001/83/EC — Medicinal products for human use — Articles 28 and 29 — Decentralised procedure for marketing authorisation for a medicinal product — Article 10 — Generic medicinal product — Data exclusivity period for the reference medicinal product — Power of the competent authorities of the Member States concerned to determine the point in time from which the exclusivity period starts to run — Jurisdiction of the courts of the Member States concerned to review the determination of the point in time from which the exclusivity period starts to run — Effective judicial protection — Charter of Fundamental Rights of the European Union — Article 47.

Interprets

    Read from EU:s publikationsbyrå, Cellar (EUR-Lex och CURIA) on 2026-08-22.

    The row repeats what the source states. It is not a summary, not a conclusion about any single case and not legal advice.

    Verifiable trust signals

    • Six fixed blocks, one source per line
    • No sentence written by a language model
    • Engine version and read date on every answer
    • No customer data, no documents, no advice
    • Model card and audit published under the EU AI Act

    Model cardAudit